申请人应用临床药物导向、活性天然产物导向、关键药物靶标导向三种研究策略，开展针对阿尔茨海默症(AD)和缺血性脑卒中的药理新机制研究和创新药物研发。首次阐明AD治疗药物—经典胆碱酯酶抑制剂石杉碱甲和多奈哌齐存在靶向干预亚细胞线粒体的非胆碱能神经保护新机制，首次发现抗缺血性脑卒中候选化合物B-CA存在TRPV1通道密切相关的控温保护药理作用新机制。完成8226多个小分子体内外药理药效评价，获得活性化合物315个，完成4个候选药物的系统临床前药效学评价。累计发表SCI论文62篇，其中第一或通讯作者34篇，总影响因子190+，发表文章共计被SCI-E他引757次，单篇最高被他引96次。申请专利11项，获发明专利证书7项。获中国药理学会“施维雅青年药理工作者奖”、上海市科技“启明星”称号和上海市青年五四奖章。

The applicant has applied three effective strategies (the exisiting drug-directed, natural product-directed, key drug target-directed methods) to clarify novel pharmacological mechanisms and discover potent drug candidates for the treatment of Alzheimer’s disease (AD) and ischemic stroke. The applicant for the first time clarified the mitochondria-targeted non-cholinergic pharmacological mechanisms of classic cholineterase inhibitors including huperzine A and donepezil, and firstly discovered that anti-ischemic stroke drug candidate B-CA possesses hypothemia-medicated novel neuroprotective mechanism, which may be closely associated with activating TRPV1 channel. Moreover, the applicant has screened 8226 small molecules, discovered 315 active compounds, in which 4 drug candidates have finished pre-clinical pharmacological efficacy evaluation. The applicant has published 62 SCI papers, with 34 first author or corresponding author SCI papers. Total IF of her publication is >190, with 757 non-self-citations, in which the top cited paper has 96 non-self citations. She has applied 11 patents, and is issued 7 invention patent certification. The applicant was awarded “CNPHARS-SERVIER Young Investigator Awards in Pharmacology” by the Chinese Pharmacological Society, and selected for the Shanghai Rising-Star Program and the “Shanghai Youth May 4th Medal”.